GlassScriptPhysician profile
Ron A Shatzmiller
NPI 1417152042
$710.03
in general payments reported to CMS, 2019-2025
10 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.46 · 2023: $166 · 2024: $65.85 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.58 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $234.16 | 2022-2025 | Wakix |
| Ucb, INC. | $213.22 | 2025 | Rystiggo, Zilbrysq |
| Genentech USA, INC. | $61.45 | 2025 | Ocrevus Zunovo |
| Bausch Health US, LLC | $45.41 | 2022-2024 | Aplenzin |
| Acadia Pharmaceuticals INC | $33.86 | 2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $33.46 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $26.38 | 2022 | |
| Sage Therapeutics, LLC | $25.56 | 2024 | |
| Lilly USA, LLC | $19.62 | 2025 | Zepbound |
| Lundbeck LLC | $16.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Shatzmiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.